2 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow SB656933: new trials by email Literature Review of SB656933 trials Research Report on SB656933
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 28 Day Repeat Dose in Cystic Fibrosis Patients SB656933, Placebo - Cystic Fibrosis | Phase 2 | Completed | GlaxoSmithKline | 146 | 2009-09-28 | 2017-11-17 |
| Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis SB-656933 - Colitis, Ulcerative | Phase 2 | Terminated | GlaxoSmithKline | 3 | 2009-01-22 | 2020-10-30 |
| SD Cystic Fibrosis Study SB656933 - Cystic Fibrosis | Phase 1 | Completed | GlaxoSmithKline | 9 | 2008-02-01 | 2012-03-19 |
Cystic Fibrosis (2) · Colitis, Ulcerative (1)
GlaxoSmithKline (3)
United States (2) · Canada (1) · France (1) · Germany (1) · Israel (1) · Netherlands (1)